New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities.

NEW YORK , July 21, 2025 /PRNewswire/ -- Renalytix Plc, a precision medicine company focused on chronic disease, and MVP Health Care, a regional, not-for-profit health insurer serving the Northeast, announced last Thursday a groundbreaking partnership designed to expand access to innovative kidney care and improve health outcomes for individuals living with type 2 diabetes and chronic kidney disease. By combining advanced diagnostics with MVP's commitment to equitable, high-quality care, the collaboration aims to identify patients at higher risk for progressive decline in kidney function earlier, enabling clinicians to target resources, therapeutic options, and care plans more appropriately. This approach will increase the chance for slowing disease progression and improving patient outcomes, including those associated with cardiovascular and metabolic conditions.

Through this partnership, MVP Health Care and Renalytix will collaborate with physician groups across MVP's network to introduce and implement the kidneyintelX.dkd™ FDA-approved test. By making this innovative technology more accessible to providers and patients, the partnership supports earlier intervention, more personalized care plans, and healthier, more independent lives.

"At MVP Health Care, we are committed to delivering innovative, affordable solutions that improve access to care and support better health for our members," said MVP Health Care's President, Dr. Richard Dal Col. "This partnership with Renalytix reflects our mission to empower both providers and patients with the tools they need to make informed, proactive decisions about their health care journey. For our customers living with type 2 diabetes and CKD, this means earlier insights, more personalized support, and a better path forward."

The kidneyintelX.dkd™ test will be available to all MVP customers in New York, including those with Medicare or Medicaid, and is recommended by KDIGO — the international clinical guideline organization for kidney disease.

"Forward-thinking in its approach, MVP Health Care is bringing together the right partners to address the growing and costly CKD epidemic," said James McCullough, CEO of Renalytix. "Where kidneyintelX.dkd is in use, we are seeing measurable improvements in patient outcomes and quality metrics, including HEDIS measures for blood pressure and HbA1c control in high-risk populations. We're proud to work alongside MVP to make this level of care more widely available."

To learn more about Renalytix, visit renalytix.com, and for information about the kidneyintelX.dkd test, visit kidneyintelx.com.

About Renalytix 
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

About MVP Health Care
MVP Health Care is a nationally recognized, not-for-profit health insurer caring for members in New York and Vermont. Committed to the complete well-being of the members and the communities it serves, MVP makes health insurance more convenient, more supportive, and more personal. For more information visit www.mvphealthcare.com or on Facebook, Twitter, Instagram, and LinkedIn.

For further information, please contact:

 

View original content:https://www.prnewswire.com/news-releases/mvp-health-care-and-renalytix-partner-to-bring-life-changing-kidney-disease-testing-to-local-communities-302509197.html

SOURCE Renalytix plc